1.The effect of ipriflavone on postmenopausal osteoporosis.
Young Joon WEON ; Yoon Sok CHUNG ; Ki Young HONG ; Yoo Kyoung PARK ; Hee Son KIM ; Jong Ho LEE ; Eun Jig LEE ; Sung Kil LIM ; Kyung Rae KIM ; Hyun Chul LEE ; Kap Bum HUH
Journal of Korean Society of Endocrinology 1993;8(3):259-264
No abstract available.
Female
;
Humans
;
Osteoporosis, Postmenopausal*
2.New Approaches to the Diagnosis and Treatment of Postmenopausal Osteoporosis.
Journal of Korean Society of Endocrinology 2006;21(2):91-100
No abstract available.
Diagnosis*
;
Female
;
Humans
;
Osteoporosis, Postmenopausal*
3.Romosozumab for the treatment of osteoporosis
Osteoporosis and Sarcopenia 2018;4(1):11-15
Romosozumab, a specific inhibitor of sclerostin, is a unique approach to therapy for postmenopausal osteoporosis and related disorders. The elucidation of sclerostin deficiency as the molecular defect of syndromes of high bone mass with normal quality, and the pivotal role of sclerostin as a mediator of osteoblastic activity and bone formation, provided the platform for the evaluation of inhibitors of sclerostin to activate bone formation. An extensive preclinical program and 2 large fracture endpoint trials with romosozumab, a sclerostin-binding antibody, have been completed. This review will highlight the results of those studies and describe the current status of romosozumab as a potential therapy for osteoporosis.
Female
;
Humans
;
Osteoblasts
;
Osteogenesis
;
Osteoporosis
;
Osteoporosis, Postmenopausal
4.Atypical Femoral Fracture Combined with Osteonecrosis of Jaw During Osteoporosis Treatment with Bisphosphonate.
Yougun WON ; Joon Ryul LIM ; Young Hwan KIM ; Hyung Keun SONG ; Kyu Hyun YANG
Journal of Bone Metabolism 2014;21(2):155-159
Bisphosphonate, a potent anti-resorptive agent, is generally accepted as a safe, effective, well tolerated treatment for postmenopausal osteoporosis. Atypical femoral fracture (AFF) and bisphosphonate related osteonecrosis of jaw (BRONJ) are the increasing morbidities in patients treated with long term bisphosphonate. Pathogenic mechanisms of AFF and BRONJ are not fully identified and not identical. We report a case of BRONJ followed by AFF and its nonunion in a 67-year-old woman patient receiving an oral bisphosphonate during 7 years for the treatment of osteoporosis.
Aged
;
Female
;
Femoral Fractures*
;
Humans
;
Jaw*
;
Osteonecrosis*
;
Osteoporosis*
;
Osteoporosis, Postmenopausal
5.Repetitive Insufficiency Fractures of the Femoral Shaft: A Case Report.
Ji Hwan KIM ; Young Ho CHO ; Young Soo BYUN ; Jung Hoon SHIN ; Chung Yeol LEE ; Tae Gyun KIM
Journal of the Korean Fracture Society 2010;23(1):109-112
Stress fractures occur when the loads applied to a bone exceed the mechanical resistance and fall into two groups. Fatigue fractures, in which abnormal mechanical stress is applied to a normal bone, and insufficiency fractures, in which fracture occurs when stress of normal activity is applied to a bone that has decreased elastic resistance. Femoral shaft insufficiency fractures are reported rarely in patients with postmenopausal osteoporosis. We report a case of repetitive insufficiency fractures of the femoral shaft in 70 year-old female with marked osteoporosis.
Female
;
Fractures, Stress
;
Humans
;
Osteoporosis
;
Osteoporosis, Postmenopausal
;
Stress, Mechanical
6.The Level of Physical Function and Psychological Well-Being of Postmenopausal Middle-aged Korean Women according to Bone Health Status.
Soon Lae KIM ; Kyeong Sook CHA
Journal of Korean Academy of Community Health Nursing 2006;17(1):46-55
OBJECTIVE: This study is to examine the physical function, psychological well-being, and subjective symptom of postmenopausal osteoporotic women. METHODS: Data used for this study was collected from 397 women who had experienced one years or longer menopause and visited a hospital in Seoul, Korea during the period from May to December 2005. RESULTS: The level of physical function of the fracture osteoporosis group was significantly lower than the other three groups. The psychological well-being of the fracture osteoporosis group was significantly lower than the other three groups. Subjective symptom of the fracture osteoporosis group was significantly higher than the other three groups. The level of physical function was positively correlated with psychological well-being and negatively with subjective symptom. Psychological well-being was also negatively correlated with the level of subjective symptom. Based on the results, it is recommended that the prevention of vertebral fracture in osteoporotic woman is important, and nursing intervention is necessary for the physical function, psychological well-being, and subjective symptom care.
Female
;
Humans
;
Korea
;
Menopause
;
Nursing
;
Osteoporosis
;
Osteoporosis, Postmenopausal
;
Seoul
7.Effect of embedding thread at Shenshu (BL 23) on clinical pain of postmenopausal osteoporosis.
Zhi-wei LIN ; Jian LI ; Li-ping GAO ; Xia-ling ZHANG
Chinese Acupuncture & Moxibustion 2005;25(12):844-846
OBJECTIVETo explore the effect of embedding thread at Shenshu (BL 23) on clinical pain of postmenopausal osteoporosis.
METHODSFifty-six cases were randomly divided into an embedding thread group, an embedding thread plus Leli group and a Leli group. The pain of the patient before treatment, 3 months and 6 months after treatment were assessed.
RESULTSThere was significant difference before and after treatment in the score of pain in both the embedding thread group and the embedding thread plus Leli group (P < 0.001), with no significant difference between the two groups (P > 0.05); there was no significant difference before and after treatment in the score of pain in the Leli group (P > 0.05), but with significant differences as compared with other two groups (both P < 0.001).
CONCLUSIONEmbedding thread at Shenshu (BL 23) has very obvious therapeutic effect on clinical pain of postmenopausal osteoporosis, and oral administration of Leli capsule has no significantly therapeutic effect on clinical pain of postmenopausal osteoporosis.
Acupuncture Points ; Acupuncture Therapy ; Humans ; Osteoporosis, Postmenopausal ; therapy ; Pain ; Software
8.Should We Prescribe Calcium Supplements For Osteoporosis Prevention?.
Journal of Bone Metabolism 2014;21(1):21-28
Advocacy for the use of calcium supplements arose at a time when there were no other effective interventions for the prevention of osteoporosis. Their promotion was based on the belief that increasing calcium intake would increase bone formation. Our current understandings of the biology of bone suggest that this does not occur, though calcium does act as a weak antiresorptive. Thus, it slows postmenopausal bone loss but, despite this, recent meta-analyses suggest no significant prevention of fractures. In sum, there is little substantive evidence of benefit to bone health from the use of calcium supplements. Against this needs to be balanced the likelihood that calcium supplement use increases cardiovascular events, kidney stones, gastrointestinal symptoms, and admissions to hospital with acute gastrointestinal problems. Thus, the balance of risk and benefit seems to be consistently negative. As a result, current recommendations are to obtain calcium from the diet in preference to supplements. Dietary calcium intake has not been associated with the adverse effects associated with supplements, probably because calcium is provided in smaller boluses, which are absorbed more slowly since they come together with quantities of protein and fat, resulting in a slower gastric transit time. These findings suggest that calcium supplements have little role to play in the modern therapeutics of osteoporosis, which is based around the targeting of safe and effective anti-resorptive drugs to individuals demonstrated to be at increased risk of future fractures.
Biology
;
Calcium*
;
Calcium, Dietary
;
Diet
;
Female
;
Humans
;
Kidney Calculi
;
Myocardial Infarction
;
Osteogenesis
;
Osteoporosis*
;
Osteoporosis, Postmenopausal
9.More than 6 Months of Teriparatide Treatment Was More Effective for Bone Union than Shorter Treatment Following Lumbar Posterolateral Fusion Surgery.
Seiji OHTORI ; Sumihisa ORITA ; Kazuyo YAMAUCHI ; Yawara EGUCHI ; Nobuyasu OCHIAI ; Kazuki KUNIYOSHI ; Yasuchika AOKI ; Junichi NAKAMURA ; Masayuki MIYAGI ; Miyako SUZUKI ; Gou KUBOTA ; Kazuhide INAGE ; Takeshi SAINOH ; Jun SATO ; Yasuhiro SHIGA ; Koki ABE ; Kazuki FUJIMOTO ; Hiroto KANAMOTO ; Gen INOUE ; Kazuhisa TAKAHASHI
Asian Spine Journal 2015;9(4):573-580
STUDY DESIGN: Retrospective case series. PURPOSE: To examine the most effective duration of teriparatide use for spinal fusion in women with postmenopausal osteoporosis. OVERVIEW OF LITERATURE: We reported that daily subcutaneous injection of teriparatide (parathyroid hormone) significantly improved bone union after instrumented lumbar posterolateral fusion (PLF) in women with postmenopausal osteoporosis when compared with oral administration of bisphosphonate. However, the most effective duration of teriparatide use for spinal fusion has not been explored. METHODS: Forty-five women with osteoporosis diagnosed with degenerative spondylolisthesis from one of the three treatment groups were evaluated based on: short-duration treatment (average, 5.5 months; n=15; daily subcutaneous injection of 20 microg teriparatide), long-duration treatment (average, 13.0 months; n=15; daily subcutaneous injection of 20 microg teriparatide), and bisphosphonate treatment (average, 13.0 months; n=15; weekly oral administration of 17.5 mg risedronate). All patients underwent PLF with a local bone graft. Fusion rate and duration of bone union were evaluated 1.5 years after surgery. RESULTS: Bone union rate and average duration for bone union were 92% and 7.5 months in the long-duration treatment group, 80% and 8.5 months in the short-duration treatment group, and 70% and 10.0 months in the bisphosphonate treatment group, respectively. Results of bone union rate and average duration for bone union in the teriparatide treatment groups were significantly superior to those in the bisphosphonate treatment group (p<0.05); whereas, significantly superior results were observed in long-duration treatment group when compared with short-duration treatment group (p<0.05). CONCLUSIONS: Daily injection of teriparatide for bone union was more effective than oral administration of bisphosphonate. Furthermore, a longer period of teriparatide treatment for bone union was more effective than a shorter period of same treatment.
Administration, Oral
;
Female
;
Humans
;
Injections, Subcutaneous
;
Osteoporosis
;
Osteoporosis, Postmenopausal
;
Retrospective Studies
;
Spinal Fusion
;
Spondylolisthesis
;
Teriparatide*
;
Transplants
10.Denosumab for the treatment of osteoporosis.
Osteoporosis and Sarcopenia 2017;3(1):8-17
Denosumab, a specific inhibitor of RANK ligand, is a novel therapy for postmenopausal osteoporosis and related disorders. An extensive clinical development program has evaluated the clinical efficacy and safety of denosumab with several thousand patients being followed for up to 10 years. Combined with more than six years of postmarketing experience, these studies provide substantial confidence that denosumab is a convenient and appropriate treatment for patients, including Asians, at high risk for fracture. This review will summarize the clinical development of denosumab and lessons learned since its approval for clinical use in 2010.
Asian Continental Ancestry Group
;
Denosumab*
;
Female
;
Humans
;
Osteoporosis*
;
Osteoporosis, Postmenopausal
;
RANK Ligand
;
Treatment Outcome